Drug Profile
Diroleuton - DS Biopharma
Alternative Names: 8,11,14-eicosatrienoic-acid; all-cis-8,11,14-eicosatrienoic-acid; Bishomo-gamma-linolenic acid; DGLA; DHLA; Dihomogammalinolenic-acid; DS 107E; DS-107G; DS-107J; DS107; Gamma-homolinolenic-acid; Homo-gamma-linolenic-acid; RO-12-1989Latest Information Update: 25 Apr 2023
Price :
$50
*
At a glance
- Originator Dignity Sciences
- Developer DS Biopharma
- Class Anti-inflammatories; Antiacnes; Antipruritics; Eicosanoids; Omega-6 fatty acids; Skin disorder therapies; Small molecules
- Mechanism of Action CD40 antigen inhibitors; Interleukin 10 inhibitors; Tumour necrosis factor alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Acne vulgaris; Atopic dermatitis; Pruritus; Radiation-induced skin damage; Wounds
Most Recent Events
- 25 Apr 2023 Discontinued - Phase-I for Atopic dermatitis (In volunteers) in Ireland (PO)
- 25 Apr 2023 Discontinued - Phase-II for Acne vulgaris in Hungary, Germany (Topical)
- 25 Apr 2023 Discontinued - Phase-II for Atopic dermatitis in Canada, USA, South Africa (PO)